Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04237649 · ClinicalTrials.gov registry record · Early Phase 1
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors
A Early Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 77
- Enrollment target
NCT04237649 is a Early Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 77 participants.
The verdict
NCT04237649, a Early Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
The primary objective of the trial was to characterize the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose (RD) for expansion of single agent KAZ954 and KAZ954 in combination with PDR001, NIR178 and NZV930.
Interventions
- DRUG PDR001
- DRUG NIR178
- DRUG KAZ954
- DRUG NZV930
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2020-02-20 |
| Est. Completion | 2023-09-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04237649
The ClinicalTrials.gov registry entry for NCT04237649 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which PDR001 is the first listed.
NCT04237649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04237649 about?
NCT04237649 is a clinical study titled "KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors". The primary objective of the trial was to characterize the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose (RD) for expansion of single agent KAZ954 and KAZ954 in combination with PDR001, NIR178 and NZV930.
What is the current status of trial NCT04237649?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 77 participants. The study started on 2020-02-20. Estimated completion is 2023-09-15.
What interventions are being tested in trial NCT04237649?
The interventions under investigation include: PDR001 (DRUG), NIR178 (DRUG), KAZ954 (DRUG), NZV930 (DRUG).
Who is sponsoring clinical trial NCT04237649?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.